Molecular Profile-Based Adjuvant Treatment Endometrial Cancer: PORTEC-4a

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Anne-Sophie van den Heerik and Carien Creutzberg to discuss Molecular Profile-Based Adjuvant Treatment Endometrial Cancer: PORTEC-4a.

Anne-Sophie van den Heerik, MD, is a resident in radiation oncologist at the Leiden University Medical Center, The Netherlands. Her work focuses on the integration of molecular classification into endometrial cancer adjuvant therapy decision-making. Her recent publications includes the PORTEC-4a trial and the Cost-utility-analysis of molecular-integrated-profile for women with (high) intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial.

Carien Creutzberg, MD, PhD is Professor of Radiation Oncology at Leiden University Medical Center, The Netherlands. Her work focuses on improving outcomes and quality of life for women with gynaecological cancers, particularly endometrial cancer. She is the principal investigator of the landmark PORTEC trials, which have shaped international treatment guidelines, and is a leading figure in integrating molecular profiling into personalized cancer care.